| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698409 | Clinical Oncology | 2015 | 9 Pages |
Abstract
A significant proportion of watch and wait patients never receive systemic therapy, predominantly due to a decline in performance status. Patients in the ICT group were younger, had a better performance status and had non-squamous histology compared with the watch and wait group. The overall survival was longer in the patients who received ICT versus watch and wait. The watch and wait strategy is associated with a high risk of missing the opportunity for any chemotherapy and should be judiciously implemented only in carefully selected patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K. Noonan, K.M. Tong, J. Laskin, Y.Y. Zheng, B. Melosky, S. Sun, N. Murray, C. Ho,